Published in J Thromb Haemost on October 01, 2003
Venous thromboembolism. BMJ (2006) 1.52
Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. Pharmacoeconomics (2010) 1.46
Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporos Int (2013) 0.92
Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure. Mol Ther (2013) 0.89
Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporos Int (2010) 0.84
Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery. Eur J Health Econ (2007) 0.78
Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review. Crit Care (2012) 0.77
Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis. Clinicoecon Outcomes Res (2017) 0.75
Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China. Adv Ther (2016) 0.75
Comparison of postoperative complications after total hip arthroplasty among patients receiving aspirin, enoxaparin, warfarin, and factor Xa inhibitors. J Orthop (2017) 0.75
Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria. Support Care Cancer (2017) 0.75
The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 9.40
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
The economic cost of brain disorders in Europe. Eur J Neurol (2012) 3.53
Economic evaluation of pharmaceuticals: a European perspective. Pharmacoeconomics (1993) 2.96
Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2. J Exp Med (1983) 2.61
The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein. Mol Cell Biol (1996) 2.57
An economic approach to clinical trial design and research priority-setting. Health Econ (1997) 2.54
Localization of the X inactivation centre on the human X chromosome in Xq13. Nature (1991) 2.48
Insulin resistance syndrome in a representative sample of children and adolescents from Quebec, Canada. Int J Obes Relat Metab Disord (2004) 2.26
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation (1996) 2.23
Fracture risk following an osteoporotic fracture. Osteoporos Int (2003) 2.21
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann Oncol (2008) 2.12
The determinants and effects of health expenditure in developed countries. J Health Econ (1992) 2.03
A comparison of five stroke scales with measures of disability, handicap, and quality of life. Stroke (1993) 2.02
Current trends in the use of pharmacoeconomics and outcomes research in europe. Value Health (2006) 1.96
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst (1996) 1.93
Conversion factor instability in international comparisons of health care expenditure. J Health Econ (1991) 1.83
Team approach versus ad hoc health services for young people with physical disabilities: a retrospective cohort study. Lancet (2002) 1.81
The clinical meaning of Rankin 'handicap' grades after stroke. Stroke (1995) 1.81
Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med (1997) 1.79
Economic evaluation in health care: is there a role for cost-benefit analysis? Health Policy (1991) 1.77
Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos (2013) 1.72
Funding of headache research in Europe. Cephalalgia (2007) 1.71
Background mortality in clinical survival studies. Lancet (1993) 1.70
Outcome measurement in economic evaluation. Health Econ (1997) 1.69
Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS). Int J Clin Pract (2009) 1.66
Chromosome 14-encoded Alzheimer's disease: genetic and clinicopathological description. Ann Neurol (1994) 1.64
Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med (2000) 1.63
Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry (2006) 1.61
Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum (1999) 1.61
An econometric analysis of health care expenditure: a cross-section study of the OECD countries. J Health Econ (1992) 1.60
Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross-sectional multicentre study. Int J Clin Pract (2013) 1.58
Positional cloning of a gene involved in hereditary multiple exostoses. Hum Mol Genet (1996) 1.58
Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Arch Dermatol (2001) 1.50
Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology (2011) 1.48
Amyloidosis due to a mutation of the gelsolin gene in an American family with lattice corneal dystrophy type II. N Engl J Med (1991) 1.48
A clinical rating scale for Batten disease: reliable and relevant for clinical trials. Neurology (2005) 1.45
The adipose tissue phenotype of hormone-sensitive lipase deficiency in mice. Obes Res (2001) 1.45
Iatrogenic pneumocephalus secondary to intravenous catheterization. Case report. J Neurosurg (1999) 1.44
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost (2006) 1.44
Crystal structure of ferrochelatase: the terminal enzyme in heme biosynthesis. Structure (1997) 1.42
The Swedish National Register for lumbar spine surgery: Swedish Society for Spinal Surgery. Acta Orthop Scand (2001) 1.41
[Prognostic markers in reflux esophagitis better than wrapped up recommendations]. Lakartidningen (1992) 1.40
Assessing the value of employee training. Health Care Manage Rev (1988) 1.39
[Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended]. Lakartidningen (2000) 1.39
Cost-effectiveness analysis of the terlipressin-glycerin trinitrate combination in the pre-hospital management of acute gastro-intestinal haemorrhage in cirrhotic patients. Intensive Care Med (1999) 1.38
Health-related quality of life (EQ-5D) before and one year after surgery for lumbar spinal stenosis. J Bone Joint Surg Br (2009) 1.37
Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care (1992) 1.36
At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int (2006) 1.36
Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol (2001) 1.34
Resource allocation to brain research in Europe (RABRE). Eur J Neurosci (2006) 1.34
Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int (2007) 1.33
Infant passenger safety education in perinatal services in California. West J Med (1982) 1.32
Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy (2011) 1.29
The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand (1997) 1.27
Functional complementation of a genetic deficiency with human artificial chromosomes. Am J Hum Genet (2001) 1.26
Hepatic changes produced by a single dose of endotoxin in the mouse. Electron microscopy. Am J Pathol (1968) 1.26
Structure and evolutionary origin of the gene encoding mouse NF-M, the middle-molecular-mass neurofilament protein. Eur J Biochem (1987) 1.24
Identification of a third EXT-like gene (EXTL3) belonging to the EXT gene family. Genomics (1998) 1.24
Diabetes--the cost of illness and the cost of control. An estimate for Sweden 1978. Acta Med Scand Suppl (1983) 1.23
Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway. Gut (2003) 1.23
A large Escherichia coli O157 outbreak in Sweden associated with locally produced lettuce. Foodborne Pathog Dis (2008) 1.22
Visual analog scales for interpretation of back and leg pain intensity in patients operated for degenerative lumbar spine disorders. Spine (Phila Pa 1976) (2001) 1.21
Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model. Osteoporos Int (2006) 1.21
X11 interaction with beta-amyloid precursor protein modulates its cellular stabilization and reduces amyloid beta-protein secretion. J Biol Chem (1998) 1.21
Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med (1999) 1.18
Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int (2001) 1.18
Identification and characterization of a novel member of the EXT gene family, EXTL2. Eur J Hum Genet (1998) 1.17
Five common fallacies in estimating the economic gains of early discharge. Soc Sci Med Med Econ (1980) 1.17
Willingness to pay for antihypertensive therapy--results of a Swedish pilot study. J Health Econ (1991) 1.15
Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J Biol Chem (1994) 1.15
The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur J Health Econ (2008) 1.14
Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. Br J Surg (2000) 1.14
Diabetes: the cost of illness in Sweden. J Intern Med (1998) 1.13
Expression of a normal and variant Alzheimer's beta-protein gene in amyloid of hereditary cerebral hemorrhage, Dutch type: DNA and protein diagnostic assays. Biochem Biophys Res Commun (1990) 1.13
Hepatic changes produced by a single dose of endotoxin in the mouse. Light microscopy and histochemistry. Am J Pathol (1967) 1.13
Interleukin 10 (IL-10) gene variants and susceptibility for paediatric onset Crohn's disease. Aliment Pharmacol Ther (2009) 1.13
Measurement and modelling of sequence-specific pKa values of lysine residues in calbindin D9k. J Mol Biol (1996) 1.13
The cost of pressure ulcers in the United Kingdom. J Wound Care (2012) 1.12
The sequence and gene characterization of a 400-kb candidate region for IDDM4 on chromosome 11q13. Genomics (2001) 1.11
Health-related quality of life in patients before and after surgery for a herniated lumbar disc. J Bone Joint Surg Br (2005) 1.11
The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy (1997) 1.10
The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)--quality of life during the first 4 months after fracture. Osteoporos Int (2013) 1.08
Cell-lysate conversion of prion protein into its protease-resistant isoform suggests the participation of a cellular chaperone. Biochem Biophys Res Commun (1999) 1.08
Butyrate mediates Caco-2 cell apoptosis via up-regulation of pro-apoptotic BAK and inducing caspase-3 mediated cleavage of poly-(ADP-ribose) polymerase (PARP). Cell Death Differ (1999) 1.08
The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract (2006) 1.08
Atypical MR appearance of Lhermitte-Duclos disease with contrast enhancement. AJNR Am J Neuroradiol (1995) 1.07
Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem (1994) 1.07
No relationship between epidural fibrosis and sciatica in the lumbar postdiscectomy syndrome. A study with contrast-enhanced magnetic resonance imaging in symptomatic and asymptomatic patients. Spine (Phila Pa 1976) (1995) 1.06
Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int (2008) 1.06
The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity (2011) 1.04
Anorectal myomectomy in the treatment of short segment Hirschsprung's disease. Ann Surg (1969) 1.03
Detection of virus-specific IgA antibodies in serum of kidney transplant patients with recurrent cytomegalovirus infection by enzymeimmuno and radioimmunoassay techniques. Clin Exp Immunol (1982) 1.02
Malabsorption, hypocholesterolemia, and fat-filled enterocytes with increased intestinal apoprotein B. Chylomicron retention disease. Gastroenterology (1987) 1.02
The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics (1998) 1.02